BioNTech SE (BNTX) Reports Q1 Loss of EUR0.24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioNTech Announces First Quarter 2020 Financial Results and Corporate Progress
May 12, 2020 8:05 AM EDTGlobal Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose escalation phase in Europe and the U.S.; first cohorts dosed in both regionsBNT122 Phase 1/2 trial update expected at AACR Virtual Annual Meeting II in JuneEnded 1Q 2020 with cash equivalents of $495Â million (452Â million) with additional $236Â million (217Â million) in equity investments and non-dilutive upfront payments due in 2Q 2020 from Pfizer and Fosun PharmaConference call and webcast scheduled for May 12, 2020 at 08:00... More
